AN2 Therapeutics, Inc. [Rocket]

Overview

AN2 Therapeutics, Inc.

Add to portfolio

Recent News + Filings (All items)

Date Filed	Type	Description
10/03/2023	4	Aziz Kabeer (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.
10/03/2023	4	Adjuvant Global Health Technology Fund, L.P. (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.
10/02/2023	144	Form 144 - Report of proposed sale of securities:
09/29/2023	4	Adjuvant Global Health Technology Fund, L.P. (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.
09/29/2023	4	Aziz Kabeer (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.
09/29/2023	144	Form 144 - Report of proposed sale of securities:
08/25/2023	4	Adjuvant Global Health Technology Fund, L.P. (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-21	Dec-31-20
Revenues	16.2	5.4
Revenue growth	201.1%
Cost of goods sold	21.6	7.3
Gross profit	-5.4	-1.9
Gross margin	-33.5%	-35.7%
General and administrative	4.7	1.3
EBIT	-21.6	-7.3
EBIT margin	-133.5%	-135.7%
Pre-tax income	-21.5	-13.6
Income taxes	0.0	0.0
Tax rate	0.0%	0.0%
Net income	-21.5	-13.6
Net margin	-133.3%	-253.5%

Diluted EPS	($8.17)	($5.30)
Shares outstanding (diluted)	2.6	2.6

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy